ARID1A and neoplasm: We found that the immune scores and immune checkpoint expression in CIC, IDH1 and ARID1A mutant group were obviously lower than that in wildtype, suggesting that the body can better recognize the mutated antigen cells and promote the immune function of T cells to better remove the antigen and inhibit tumour development.